NCT03485222View on ClinicalTrials.gov

"Are the Cardiac Benefits of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4)."

PHASE4CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

May 21, 2018

Primary Completion Date

February 13, 2020

Study Completion Date

February 13, 2020

Conditions
Cardiovascular Diseases
Interventions
DRUG

Empagliflozin

6 months

DRUG

Placebos

placebo equivalent for 6 months

Trial Locations (1)

10029

Mount Sinai Heart - Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT03485222 - "Are the Cardiac Benefits of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4)." | Biotech Hunter | Biotech Hunter